Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project
Launched by M.D. ANDERSON CANCER CENTER · Mar 10, 2025
Trial Information
Current as of April 23, 2025
Not yet recruiting
Keywords
ClinConnect Summary
Primary Objective:
To establish MD Anderson Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project.
* To prospectively identify, collect, and store all isolates causing proven or probable MCM in adult high-risk cancer participants.
* To prospectively identify, collect, and store relevant host samples from high-risk participants developing proven or probable MCM, along with relevant biospecimens from three control groups.
* To comprehensively annotate clinical specimens and provide information regarding the course and outcome of all MCM cases and controls.
OUTLINE:
This is an obser...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients must be 18-100 years old and have cancer and invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection but no evidence of such infection.
- • Patients must be willing to undergo routine diagnostic procedures (e.g., phlebotomy, bronchoscopy, biopsy) as part of their regular care.
- Exclusion Criteria:
- • • Patients who are unwilling to undergo routine diagnostic procedures as part of their regular care.
Trial Officials
Dimitrios Kontoyiannis, MD
Principal Investigator
M.D. Anderson Cancer Center
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported